Pseudogout treatment revolves around tamping down inflammation during painful flares and, when attacks keep recurring, taking steps to reduce their frequency. Unlike gout, where medications can lower uric acid and eventually dissolve the offending crystals, there is no approved drug that removes calcium pyrophosphate (CPP) crystals from cartilage once they have formed. That gap shapes the entire treatment strategy: you manage the symptoms and the inflammatory cascade the crystals provoke, because the crystals themselves are staying put. The good news is that several effective options exist for each stage of the disease, from a sudden swollen knee to years of recurring joint pain.
Putting Out the Fire During an Acute Flare
When a pseudogout flare strikes, the immediate goal is pain relief and reducing swelling. Three first-line medications cover most situations, and European guidelines from EULAR treat them as roughly interchangeable depending on the patient’s other health conditions.
NSAIDs are often the go-to choice for otherwise healthy adults. Any over-the-counter or prescription NSAID can work; there is no evidence that one outperforms another for CPP crystal arthritis. European guidelines recommend starting a full-dose course when the flare begins and then tapering once symptoms improve, usually stopping a day or two after the joint settles down. Side effects like stomach irritation and kidney strain are uncommon with these short courses, but they become a real concern in older adults with chronic kidney disease, heart failure, or a history of stomach ulcers.1Frontiers in Medicine. Recent advances in the therapeutic management of calcium pyrophosphate deposition disease
Colchicine is the other classic option. The dosing for a pseudogout flare is low compared to what was historically prescribed for gout: a loading dose followed by a smaller dose an hour later, then a maintenance dose the next day. A multicenter randomized trial directly compared low-dose colchicine against oral prednisone for acute CPP arthritis and found them essentially equivalent. Pain scores dropped by about the same amount in both groups at 24 hours.2Arthritis & Rheumatology. Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition Arthritis: A Multicenter Randomized Controlled Trial Colchicine does need dose adjustment in people with kidney problems, and diarrhea is the most common annoyance.
Corticosteroids fill the gap when NSAIDs and colchicine are both off the table. Oral prednisone at a moderate dose for a few days works well for a single flare. For a single large joint that is acutely swollen, many rheumatologists prefer to aspirate the joint fluid and inject a corticosteroid directly into the joint space. Joint aspiration doubles as a diagnostic tool, since identifying CPP crystals under polarized light microscopy is the gold standard for confirming pseudogout. Draining the fluid also relieves pressure immediately, which patients tend to appreciate.
When Standard Treatments Fall Short
Most pseudogout flares respond to one of the three options above within a few days. But some people have attacks that keep roaring back despite treatment, or they cannot tolerate any of the standard medications because of kidney disease, drug interactions, or severe gastrointestinal problems. This is where the picture gets more complicated and less evidence-based, because pseudogout has attracted far less clinical trial attention than gout.
The most promising option for refractory flares targets the inflammatory molecule at the center of the crystal response: interleukin-1 beta (IL-1β). When CPP crystals land in joint fluid, they activate a specific part of the immune system’s alarm machinery in macrophages, ramping up IL-1β production and driving the intense inflammation you feel as heat, swelling, and pain.3Annals of the Rheumatic Diseases. Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages Anakinra, a drug that blocks the IL-1 receptor, has been used off-label to shut down that pathway directly. Case reports describe patients with stubborn pseudogout who responded to anakinra within two weeks, with inflammation markers returning to normal.4PubMed. Successful treatment of resistant pseudogout with anakinra
Anakinra has also shown promise in one of the trickiest patient groups: people on dialysis for end-stage kidney disease, who cannot safely take NSAIDs or colchicine. In reported cases, anakinra resolved chronic CPP arthritis in dialysis patients and allowed them to stop corticosteroids entirely, with continued remission as long as the drug was maintained.5PubMed Central. Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis The evidence here is still limited to case reports and small series, not large trials, so anakinra remains a specialist-level decision rather than something your primary care doctor is likely to reach for first. But for patients who have run out of conventional options, it represents a genuinely useful tool.
Preventing Flares From Coming Back
If you have had one pseudogout flare, there is a decent chance you will have another. The crystals do not disappear between attacks; they sit quietly in the cartilage until something triggers a fresh round of inflammation. For people who experience several flares a year, daily low-dose colchicine is the main prophylactic strategy.
The clearest evidence for this approach comes from a study of patients who averaged about three pseudogout attacks per year before starting colchicine. On the drug, attack frequency dropped to roughly one per year, and ninety percent of patients saw some benefit.6PubMed. Colchicine prophylaxis in pseudogout The mechanism makes pharmacological sense: colchicine interferes with the inflammasome pathway that CPP crystals activate, essentially raising the threshold the immune system needs to reach before launching a full inflammatory response.7PubMed Central. Treatment and management of pseudogout: insights for the clinician
Prophylactic colchicine is typically prescribed at a lower dose than what you would take during a flare, and it needs to be taken consistently, often for months or longer. It is not a cure; stop the drug, and flares can return. The side-effect profile at these low doses is mild for most people, with loose stools being the most common complaint, but your doctor will want to check kidney and liver function periodically.
Living With Chronic CPP Crystal Arthritis
Some people develop a pattern that goes beyond discrete flares separated by pain-free intervals. Chronic CPP crystal inflammatory arthritis looks more like rheumatoid arthritis, with persistent joint stiffness, low-grade swelling, and ongoing discomfort. When daily colchicine alone is not enough to keep symptoms controlled, clinicians sometimes turn to disease-modifying drugs borrowed from the rheumatoid arthritis toolkit.
Methotrexate is the most commonly added agent. A European cohort study found that colchicine was used as first-line therapy in the vast majority of chronic CPP cases, and it controlled symptoms well enough to be sustained for two years in about a third of patients. When colchicine fell short, methotrexate was frequently the next step, often co-prescribed with colchicine or low-dose corticosteroids.8Rheumatology. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis The results for methotrexate in dedicated trials have been mixed, however. A systematic review of the very limited randomized trial evidence found that hydroxychloroquine and magnesium supplementation showed some efficacy for reducing pain in CPPD, while methotrexate results were less convincing on their own.9Seminars in Arthritis and Rheumatism. Management of calcium pyrophosphate crystal deposition disease: A systematic review
The honest picture is that chronic CPP arthritis management is largely empirical. Clinicians cycle through available options based on what each patient tolerates and responds to, guided more by clinical experience than by robust trial data. Only three randomized controlled trials had been identified as of the most recent systematic review, which underscores just how under-researched this disease remains compared to other forms of arthritis.
Metabolic Conditions That Deserve a Closer Look
Pseudogout sometimes shows up as a secondary consequence of an underlying metabolic disorder, and recognizing that connection can change how you approach treatment. The most important conditions to rule out are hyperparathyroidism, hemochromatosis, and hypomagnesemia.
Hyperparathyroidism is the classic association. In a series of 20 patients with pseudogout, eight had intermittent attacks that ultimately led to the diagnosis of primary hyperparathyroidism. The connection goes both ways: excess parathyroid hormone raises calcium levels, which promotes CPP crystal deposition in cartilage. And after parathyroid surgery, the abrupt drop in calcium can trigger crystal shedding from cartilage into the joint space, provoking a fresh attack.10PubMed. Pseudogout as a clue and complication in primary hyperparathyroidism Doctors treating pseudogout in relatively young patients, or patients with recurrent attacks that seem out of proportion to their age, will often check calcium and parathyroid hormone levels for exactly this reason.
Hemochromatosis, the iron-overload condition, is another recognized trigger. Joint involvement in hemochromatosis can mimic osteoarthritis or pseudogout, and CPP crystal deposition is a well-documented feature.11PubMed Central. Clinical and roentgenographic aspects of pseudogout: a study of 50 cases and a review Hypomagnesemia, or chronically low magnesium, is less commonly screened for but deserves attention, especially in younger patients with CPPD. Magnesium is a natural inhibitor of CPP crystal formation, and when levels are low, crystal deposition can accelerate. Causes of hypomagnesemia range from certain diuretics and proton pump inhibitors to rare genetic tubular disorders.12PubMed Central. Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review
When one of these metabolic conditions is found and treated, pseudogout attacks sometimes improve or even stop, though the crystal deposits already present in the cartilage tend to persist. Still, correcting the underlying cause is one of the few situations in pseudogout management where you are addressing the root of the problem rather than just managing the immune response.
Treatment Challenges in Older Adults
Pseudogout overwhelmingly affects older adults. The typical patient is over 65, and many are in their 70s or 80s. This creates a constant tension in treatment: the drugs that work best for flares are precisely the ones that become riskier with age and accumulating health problems.
NSAIDs are the clearest example. A brief course is well tolerated in a healthy 55-year-old but can cause kidney injury, gastrointestinal bleeding, or fluid retention in someone with even moderate kidney impairment or heart failure. Colchicine requires dose reduction in kidney disease and becomes dangerous in severe renal impairment. In patients with both kidney disease and CPPD, both NSAIDs and colchicine may be ruled out entirely, leaving corticosteroids, ACTH injections, or disease-modifying agents as the remaining options.13Exploration of Musculoskeletal Diseases. Treatment strategies for calcium pyrophosphate deposition disease
Corticosteroids work reliably for acute flares, but repeated use carries its own costs: bone thinning, blood sugar spikes in diabetics, increased infection risk, and muscle weakness. For an older adult who has three or four flares a year, rotating through short prednisone courses is not a great long-term plan. This is exactly the scenario where prophylactic colchicine at a low dose, if kidney function allows, becomes worthwhile. And for the subset of patients for whom even low-dose colchicine is unsafe, anakinra represents a meaningful, if expensive and logistically demanding, alternative.
Crowned Dens Syndrome and Other Unusual Presentations
Most people associate pseudogout with the knee, which is indeed the most commonly affected joint. But CPP crystals can deposit in cartilage and ligaments throughout the body, and one of the more striking locations is the spine. Crowned dens syndrome occurs when CPP crystite deposits accumulate in the ligaments surrounding the odontoid process, the peg-like projection at the top of the second cervical vertebra. The result is severe neck pain, neck stiffness, and fever, often with markedly elevated inflammatory markers.
The danger with crowned dens syndrome is misdiagnosis. The combination of acute neck pain, stiffness, and fever closely mimics meningitis, and chronic relapsing forms can be mistaken for polymyalgia rheumatica or simple cervicogenic neck pain.14PubMed. Crowned dens syndrome A systematic review found that neck pain was present in nearly all cases and that CT scans were the most reliable imaging method, picking up abnormalities in about 97% of cases, compared to roughly 79% for plain X-rays and 68% for MRI.15PubMed. Clinical features and diagnostic challenges in crowned dens syndrome: a systematic review and meta-analysis
Treatment of crowned dens syndrome follows the same principles as peripheral pseudogout. NSAIDs were the most commonly used therapy, and improvement occurred in the vast majority of cases. Colchicine and corticosteroids also work. The key step is recognizing it in the first place: once a doctor considers the diagnosis and orders the right imaging, the path forward is straightforward.16PubMed Central. A Case of Acute Neck Pain: The Crowned Dens Syndrome
How Pseudogout Is Confirmed
Treatment decisions hinge on an accurate diagnosis, and pseudogout can mimic several other conditions. Gout is the obvious lookalike, but septic arthritis (an infected joint) is the one you really cannot miss, because it requires antibiotics and sometimes surgical drainage. Joint aspiration is the definitive test: examining synovial fluid under compensated polarized light microscopy reveals weakly positively birefringent rhomboid-shaped crystals in pseudogout, as opposed to the needle-shaped negatively birefringent crystals of gout. This distinction matters because treatment overlaps somewhat but is not identical, and gout has the option of long-term urate-lowering therapy that pseudogout lacks.
Imaging also plays a role. Plain X-rays can show chondrocalcinosis, the calcification of cartilage that suggests CPP crystal deposition, though its absence does not rule out pseudogout. Ultrasound and dual-energy CT (DECT) both have good sensitivity and specificity for identifying CPP and urate crystals, though their performance drops in early-stage disease with low crystal burdens.17PubMed Central. Diagnostic advances in synovial fluid analysis and radiographic identification for crystalline arthritis In practice, if joint aspiration confirms CPP crystals, imaging is not strictly necessary for diagnosis, but it can help map the extent of crystal deposition in other joints and guide expectations about recurrence.
When Surgery Enters the Picture
Surgery for pseudogout is rare and reserved for situations where crystal deposition causes structural damage that medications cannot address. The most common scenario is joint destruction in a major weight-bearing joint, where severe cartilage loss and chronic inflammation eventually point toward joint replacement, just as they would in advanced osteoarthritis. In unusual locations, surgery may be more directly prompted by the crystal deposits themselves. One reported case involved massive CPP crystal deposition in the temporomandibular joint (the jaw hinge), where the mass had eroded the condyle badly enough to require resection and total joint replacement with a prosthetic implant. The patient recovered well, returning to a normal diet with improved jaw opening.18PubMed. Pseudogout of the temporomandibular joint: immediate reconstruction with total joint arthroplasty
These surgical cases are outliers. For the overwhelming majority of people with pseudogout, the battle is pharmacological: finding the right combination of acute flare treatment, prophylaxis if flares are frequent, and screening for correctable metabolic causes. The frustrating reality is that available treatments manage the disease rather than cure it, and the evidence base remains thinner than it should be. Researchers have been calling for more randomized trials for over a decade now. Until those trials materialize, treatment will continue to lean heavily on clinical judgment, borrowed knowledge from gout research, and the small but growing body of evidence specific to CPP crystal arthritis.